Search Results

Diaceutics PLC today announced the acceptance of two abstracts for poster discussion presentation and publication in the November 2021 Journal of Molecular Diagnostics at the Association for Molecular Pathology (AMP) 2021 Annual Meeting & Expo, which will take place November 16-20 in Philadelphia.

Diaceutics PLC, (AIM: DXRX), today announces the appointment of Yvanka Gilliam as Vice President of Operations, Asia Pacific (APAC).

Diaceutics PLC, (AIM: DXRX), today announces the appointment of Nikita Lynn to Vice President of Finance. She has been promoted to this role following her tenure as Senior Director of Corporate Advancement.

Diaceutics PLC (AIM:DXRX) today announces a new partnership with LGC SeraCare (“SeraCare”), the US-based manufacturer of diagnostic test reference standard controls.

Diaceutics PLC, the diagnostic commercialisation company, today announces the acceptance of an abstract for a poster discussion presentation, discussing the impact of COVID-19 on cancer diagnosis, at the prestigious 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held virtually from June 4-8, 2021.

Diaceutics PLC, announces a strategic partnership with Canadian Pathology Quality Assurance to advance the development of Neurotrophic Tropomyosin Receptor Kinase IHC proficiency testing globally.

Diaceutics announces a series of forecasts based on research published in its annual Pharma Precision Medicine Readiness Report

Diaceutics PLC, (AIM: DXRX), the precision diagnostic commercialization company, today announces research results from its COVID-19 oncology tracker, which shows the impact of the crisis on cancer testing and diagnosis in the US

Diaceutics today reveals new data insights into key areas of cancer testing. In collaboration with the company’s network of industry advisors, the research has just been published in four abstracts and one poster at this year’s virtual American Society of Clinical Oncology (ASCO) conference

Diaceutics PLC, (AIM: DXRX), today announces the launch of DXRX – The Diagnostic Network® which has been designed to accelerate the end-to-end development and commercialization of precision medicine diagnostics by reducing time to peak biomarker test adoption for cancer testing from years to months.